GB9606372D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB9606372D0
GB9606372D0 GBGB9606372.2A GB9606372A GB9606372D0 GB 9606372 D0 GB9606372 D0 GB 9606372D0 GB 9606372 A GB9606372 A GB 9606372A GB 9606372 D0 GB9606372 D0 GB 9606372D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9606372.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791059&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9606372(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Priority to GBGB9606372.2A priority Critical patent/GB9606372D0/en
Publication of GB9606372D0 publication Critical patent/GB9606372D0/en
Priority to MYPI97001186A priority patent/MY126358A/en
Priority to NZ331645A priority patent/NZ331645A/en
Priority to BR9708238A priority patent/BR9708238A/en
Priority to PCT/EP1997/001438 priority patent/WO1997035587A1/en
Priority to HU9901887A priority patent/HU228026B1/en
Priority to ARP970101146A priority patent/AR006345A1/en
Priority to DK97914287T priority patent/DK0906107T3/en
Priority to CN97193229A priority patent/CN1225587A/en
Priority to AU21591/97A priority patent/AU724239B2/en
Priority to IDP970927A priority patent/ID16781A/en
Priority to UA98094710A priority patent/UA67723C2/en
Priority to IL12618597A priority patent/IL126185A/en
Priority to EP97914287A priority patent/EP0906107B1/en
Priority to RO98-01407A priority patent/RO119923B1/en
Priority to EE9800323A priority patent/EE04093B1/en
Priority to SI9730498T priority patent/SI0906107T1/en
Priority to SK1269-98A priority patent/SK284244B6/en
Priority to DE69718315T priority patent/DE69718315T2/en
Priority to ES97914287T priority patent/ES2190528T3/en
Priority to TW086103607A priority patent/TW455491B/en
Priority to CA002249336A priority patent/CA2249336C/en
Priority to EA199800755A priority patent/EA001484B1/en
Priority to AT97914287T priority patent/ATE230602T1/en
Priority to APAP/P/1998/001343A priority patent/AP1150A/en
Priority to PL32891697A priority patent/PL187919B1/en
Priority to JP09534017A priority patent/JP3117726B2/en
Priority to CO97015457A priority patent/CO4790151A1/en
Priority to GEAP19974496A priority patent/GEP20012464B/en
Priority to TR1998/01881T priority patent/TR199801881T2/en
Priority to CZ19983035A priority patent/CZ289958B6/en
Priority to IS4840A priority patent/IS2066B/en
Priority to OA9800171A priority patent/OA10880A/en
Priority to NO19984386A priority patent/NO317639B1/en
Priority to BG102838A priority patent/BG64457B1/en
Priority to HK99102135A priority patent/HK1016896A1/en
Priority to UY25926A priority patent/UY25926A1/en
Priority to CY0400050A priority patent/CY2444B1/en
Pending legal-status Critical Current

Links

GBGB9606372.2A 1996-03-22 1996-03-26 Pharmaceutical formulations Pending GB9606372D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
MYPI97001186A MY126358A (en) 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
TR1998/01881T TR199801881T2 (en) 1996-03-22 1997-03-21 Compositions containing an HIV protease inhibitor such as VX 478 and a water-soluble vitamin E compound such as vitamin E-TPGS.
CZ19983035A CZ289958B6 (en) 1996-03-22 1997-03-21 Pharmaceutical preparation
SK1269-98A SK284244B6 (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble Vitamin E compound such as Vitamin E-TPGS
CA002249336A CA2249336C (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
HU9901887A HU228026B1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
ARP970101146A AR006345A1 (en) 1996-03-22 1997-03-21 A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION.
DK97914287T DK0906107T3 (en) 1996-03-22 1997-03-21 Formulations containing VX478 and a water-soluble Vitamin E compound such as Vitamin E-TPGS
CN97193229A CN1225587A (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble vitamin E compound such as vitamin E-TPGS
AU21591/97A AU724239B2 (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble vitamin E compound such as vitamin E-TPGS
IDP970927A ID16781A (en) 1996-03-22 1997-03-21 PHARMACEUTICAL FORMULATIONS
UA98094710A UA67723C2 (en) 1996-03-26 1997-03-21 Pharmaceutical formulations for peroral administration and method for its preparation
IL12618597A IL126185A (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent
EP97914287A EP0906107B1 (en) 1996-03-22 1997-03-21 Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
RO98-01407A RO119923B1 (en) 1996-03-22 1997-03-21 Pharmaceutical composition for oral administration
EE9800323A EE04093B1 (en) 1996-03-22 1997-03-21 Preparations containing the HIV protease inhibitor VX 478 and the water-soluble vitamin E derivative vitamin E-TPGS
SI9730498T SI0906107T1 (en) 1996-03-22 1997-03-21 Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
NZ331645A NZ331645A (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble vitamin E compound such as vitamin E-TPGS
DE69718315T DE69718315T2 (en) 1996-03-22 1997-03-21 PREPARATION, CONTAINING VX 478 AND A WATER-SOLUBLE VITAMIN E COMPOUND LIKE VITAMIN E-TPGS
ES97914287T ES2190528T3 (en) 1996-03-22 1997-03-21 COMPOSITIONS CONTAINING VX478 AND A COMPOSITE OF VITAMIN AND SOLUBLE IN WATER, SUCH AS VITAMIN E-TPGS.
TW086103607A TW455491B (en) 1996-03-22 1997-03-21 Pharmaceutical composition for oral administration
BR9708238A BR9708238A (en) 1996-03-22 1997-03-21 Pharmaceutical formulation for oral administration and process for preparing the same
EA199800755A EA001484B1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluable vitamin e compound such as vitamin e-tpgs
AT97914287T ATE230602T1 (en) 1996-03-22 1997-03-21 PREPARATION CONTAINING VX 478 AND A WATER-SOLUBLE VITAMIN E COMPOUND SUCH AS VITAMIN E-TPGS
APAP/P/1998/001343A AP1150A (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as Vx 478 and a water soluble vitamin E compound such as vitamin E-TPGS.
PL32891697A PL187919B1 (en) 1996-03-22 1997-03-21 Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
JP09534017A JP3117726B2 (en) 1996-03-22 1997-03-21 Compositions comprising an HIV protease inhibitor such as VX478 and a water-soluble vitamin E such as vitamin E-TPGS
CO97015457A CO4790151A1 (en) 1996-03-22 1997-03-21 COMPOSITIONS INCLUDING AN HIV PROTEASE INHIBITOR LIKE VX478 AND A COMPOUND OF VITAMIN E Soluble IN WATER AS VITAMIN E - TPGS
GEAP19974496A GEP20012464B (en) 1996-03-22 1997-03-21 Compositions Comprising an HIV Protease Inhibitor Such As VX 478 and a Water Soluble Vitamin E Compound Such As Vitamin E-TPGS
IS4840A IS2066B (en) 1996-03-22 1998-08-28 Compositions comprising VX 478 and a water-soluble vitamin E compound such as vitamin E-TPGS
OA9800171A OA10880A (en) 1996-03-22 1998-09-18 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
NO19984386A NO317639B1 (en) 1996-03-22 1998-09-21 Compositions comprising an HIV protease inhibitor such as VX 478 and a water-soluble vitamin E compound such as vitamin E TPGs
BG102838A BG64457B1 (en) 1996-03-22 1998-10-12 Hiv protease inhibitor-containing pharmaceutical form for oral administration
HK99102135A HK1016896A1 (en) 1996-03-22 1999-05-12 Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin etpgs
UY25926A UY25926A1 (en) 1996-03-22 2000-01-17 PHARMACEUTICAL FORMULATIONS OF 3S- (3R * (1R *, 2S *)) - (3 - (((4-AMINOFENIL) SULFONIL) (2-METHYLPROPYL) -AMINO) -2-HYDROXY- ESTER TETRAHIDRO-3-FURANILICO 1-PHENYL METHYL) PROPIL CARBAMIC
CY0400050A CY2444B1 (en) 1996-03-22 2004-06-23 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GB9606372D0 true GB9606372D0 (en) 1996-06-05

Family

ID=10791059

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9606372.2A Pending GB9606372D0 (en) 1996-03-22 1996-03-26 Pharmaceutical formulations

Country Status (2)

Country Link
GB (1) GB9606372D0 (en)
UA (1) UA67723C2 (en)

Also Published As

Publication number Publication date
UA67723C2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
ZA953236B (en) Pharmaceutical formulations
EG23826A (en) Pharmaceutical formulations
GB9713149D0 (en) Pharmaceutical formulations
AP9600883A0 (en) Pharmaceutical formulations
GB9404248D0 (en) Pharmaceutical formulations
EG24118A (en) Pharmaceutical compositions
GB9616672D0 (en) Pharmaceutical compositions
GB9715490D0 (en) Pharmaceutical preparation
GB9610359D0 (en) Pharmaceutical compositions
EP0907644A4 (en) Pharmaceutical preparation
GB9622681D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
ZA96392B (en) Pharmaceutical formulations
GB9413542D0 (en) Pharmaceutical formulations
GB9606372D0 (en) Pharmaceutical formulations
GB9621531D0 (en) Pharmaceutical formulations
GB9500978D0 (en) Pharmaceutical formulations
GB9703607D0 (en) Pharmaceutical formulations
GB9408163D0 (en) Pharmaceutical formulations
ZA953239B (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations